Researchers found that offering hyperbaric oxygen therapy to women with late local toxic effects was ineffective for reducing pain but was effective for reducing fibrosis.
Asynchronous Bilateral Male Breast Cancer. A Rare Case Report
Source : https://foliamedica.bg/article/96190/
We describe a rare case of asynchronous bilateral carcinoma of the mammary glands in a 66-year-old man. The patient was admitted to the Department of Dermatology and Venereology due to...
This report described a rare case of asynchronous primary bilateral carcinoma of the mammary glands in a man.
Investigating Sexual Health After Breast Cancer by Longitudinal Assessment of Patient-Reported Outcomes
Source : https://pubmed.ncbi.nlm.nih.gov/38350335/
Sexual concerns seem frequent, persistent, and insufficiently addressed. Pretreatment concerns, endocrine therapy, and emotional distress are commonly associated factors. A proactive evaluation of sexual health across the care continuum is...
Sexual concerns were frequent, persistent, and insufficiently addressed. Pretreatment concerns, endocrine therapy, and emotional distress were commonly associated factors.
Chemotherapy-Induced Cognitive Impairment in Breast Cancer Survivors: a Systematic Review of Studies From 2000 to 2021
Source : https://pubmed.ncbi.nlm.nih.gov/38351543/
Chemotherapy, affecting cortical and subcortical brain structures, causes a set of cognitive impairments that can lead to impairments in social responsibility acceptance, daily functioning, and quality of life of women....
The evidence does not establish chemotherapy as the sole or primary cause of cognitive deficits, but it does point to a complex interplay of factors, including age, type of chemotherapy, and individual patient characteristics.
Optimising First-Line Subtyping-Based Therapy in Triple-Negative Breast Cancer (FUTURE-SUPER): a Multi-Cohort, Randomised, Phase 2 Trial
Source : https://pubmed.ncbi.nlm.nih.gov/38211606/
For the Chinese translation of the abstract see Supplementary Materials section.
Median PFS was significantly longer in the pooled subtyping-based group than in the control group, highlighting the potential clinical benefits of using molecular subtype-based treatment optimization.